The role of lapatinib in HER2-positive breast cancer
Journal Title: OncoReview - Year 2013, Vol 3, Issue 2
Abstract
HER2 positive breast cancer presents 25–35% of newly diagnosed cases and is associated with more aggressiveness and poorer prognosis. The anti-HER2 monoclonal antibody trastuzumab improved the outcome of women with HER positive breast cancer. Despite the primary effectiveness resistance to trastuzumab occurs. The second drug which interacts with HER2 receptor is lapatinib. There is no cross resistance between both drugs. Lapatinib is dual, reversible tyrosin kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor type 2 (HER2). Based on the results of the clinical trials the efficacy and safety of lapatinib was confirmed.
Authors and Affiliations
Małgorzata Kuc-Rajca, Tadeusz Pieńkowski, Anna Walaszkowska-Czyż
Keywords
Related Articles
- EP ID EP53216
- DOI -
- Views 208
- Downloads 0
Health and disease – medical and psychological aspects of quality of life in patients with gynecological cancers
Gynecological cancers, due to their location and relation to the aspects of femininity, reproductive ability and body image, are associated not only with the physical dimension of cancer, but also with the mental sphere....
The role of granulocyte colony-stimulating factors in the prevention of neutropenia and febrile neutropenia – the current state of knowledge
Granulocyte colony-stimulating factors, introduced in the 1990s to prevent neutropenic fever, improve patients’ prognosis after myelotoxic chemotherapy. G-CSFs accelerate bone marrow recovery, shortening the duration of...
Percutaneous retrieval of a fractured portacath fragment in two patients undergoing long-term chemotherapy
The paper discusses two clinical cases of cancer patients undergoing chemotherapy, in whom fractured and displaced tips of portacath catheters were revealed based on plain chest imaging. In the first case, the portacath...
Meeting the human. What can I get out of it?
Recently patients representatives are more often invited to oncological congresses. They would like to draw attention of the medical society to other than medical problems of people with cancer. Doctors should remember h...
Consensus statement on indications for the use of non-pegylated liposomal doxorubicin in patients with lymphomas and concomitant cardivascular diseases